Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD) Rockville, Maryland, May 26, 2023 – Sunstone Therapies, a leader in the development of clinical trials and the delivery of psychedelic-assisted therapy in the medical setting, today announces data from a long-term, 18-month follow-up…


Previous articleData Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023
Next articlePsychedelics Weekly – New LSD Research and The Challenges Facing a Rapidly Growing Psychedelic Guide Industry